Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Neuroblastoma 1 Neoplasm Metastasis 1 Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Cyclophosphamide 53 Etoposide 33 Temozolomide 28 Irinotecan 28 Melphalan 25 Filgrastim 25 Topotecan 24 Carboplatin 24 3-Iodobenzylguanidine 23 Isotretinoin 20 Granulocyte Colony-Stimulating Factor 17 sargramostim 16 humanized 3F8 anti-GD2 monoclonal antibody 16 dinutuximab 16 Granulocyte-Macrophage Colony-Stimulating Factor 16 fludarabine 15 Vincristine 15 Doxorubicin 15 Cisplatin 15 Peripheral Blood Stem Cell Transplantation 14 Interleukin-2 14 Busulfan 13 naxitamab 12 Thiotepa 12 Radiotherapy 12 aldesleukin 11 fludarabine phosphate 10 etoposide phosphate 8 Mesna 8 Ifosfamide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neuroblastoma × SF 1126 × Clear all

NCT02337309 2018-08-20

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Terminated

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡